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Intrabodies offer attractive options for manipulating the
protein misfolding that triggers neurodegenerative dis-
eases. In Huntington’s disease, where the expanded poly-
glutamine tract in the extreme N-terminal region of
huntingtin exon1 misfolds, two lead intrabodies have been
selected against an adjacent peptide, using slightly differ-
ent approaches. Both are effective at preventing aggrega-
tion of a reporter fragment in transient co-transfection
assays. However, after intracranial delivery to mutant
mouse brains, VL12.3, which is mainly localized to the
nucleus, appears to accelerate the mutant phenotype, while
C4 scFv, which is largely cytoplasmic, shows partial
phenotypic correction. This comparison highlights para-





Huntington’s disease (HD) is caused by the misfolding of the
N-terminal exon1 fragment of the protein product of a mutant
gene encoding an expanded (.36 copies) CAG trinucleotide
repeat (Hatters, 2008; Imarisio et al., 2008). The resultant
expanded polyglutamine (polyQ) has a high propensity to
adopt b-sheet structure, causing the protein to aggregate into
highly ordered amyloid fibrils and to interact abnormally with a
variety of other proteins. Striatal neurons are particularly vulner-
able to this cellular disruption, and show a phenotype that in-
cludes neuronal intranuclear inclusions and transcriptional
dysregulation. Altering the protein context of the polyQ had the
potential to alter the misfolding kinetics; therefore, an intrabody
approach seemed justified. Using the Sheets single-chain Fv
(scFv) library from the Marks lab (Sheets et al., 1998), a selection
against the N-terminal 17AA adjacent to the polyQ (Fig. 1A)
was used to generate a candidate construct, C4 scFv, that has
shown efficacy against the aggregation and/or toxicity pheno-
types in cellular, organotypic slice culture, Drosophila and
transgenic mouse models of HD (Lecerf et al., 2001; Murphy
and Messer, 2004; Miller et al., 2005; Wolfgang et al., 2005;
Snyder-Keller et al., 2010; Butler and Messer, 2011).
In an effort to further enhance efficacy, a subsequent selec-
tion vs AAs 1–20 (Fig. 1A) including the first 3 glutamine
residues was performed by Colby et al., using a yeast surface
display library. After multiple rounds of engineering to
improve intracellular stability and increase affinity, the result-
ant VL12.3 was able to correct misfolded Huntingtin exon1
(Httex1) protein at lower concentrations than scFv when tested
in co-transfection assays (Colby et al., 2004a,b). However, in
vivo efficacy was sub-optimal, including accelerated onset of
multiple phenotypic markers (Southwell et al., 2008, 2009).
VL12.3, particularly when complexed with its Httex1 target,
appears to reside primarily in the nucleus (Southwell et al.,
2008, 2009). Given the multiple observations of a potential
mode of HD toxicity via nuclear processes, including a more
aggressive disease phenotype when an Httex1 transgene was
directly fused to a nuclear localization signal (NLS; Davies
et al., 1997; DiFiglia et al., 1997; Steffan et al., 2000; Benn
et al., 2005, 2008; Atwal et al., 2007), we now show that
C4 scFv is primarily cytoplasmic when compared with VL12.3
over a range of assay systems, and confirm C4 scFv cytoplas-
mic localization in brain cells by confocal microscopy. This
intrabody also does not accelerate overall disease parameters
of weight loss and early death. These data illustrate the critical
merging of improved understanding of the disease mechan-




cDNAs encoding the intrabodies in pAAV—C4 scFv (GenBank
accession number EU490426) and VL12.3—were used as previ-
ously described (Colby et al., 2004a,b; Kvam et al., 2009). For
the nuclear export signal (NES) control experiments, DNA was
polymerase chain reaction (PCR) amplified using complemen-
tary primers that encoded mitogen-activated protein kinase
kinase NES. The resulting PCR product was ligated into pAAV-
MCS (Stratagene) at the corresponding Xba1 and HindIII
restriction sites using standard cloning techniques. The resulting
expression plasmid cassette was the following: pAAV-
MCS-Kozak sequence-C4 scFv-NES-HA-stop or pAAV-MCS-
Kozak sequence-VL12.3NES-HA-stop. Human Httex1 with 72
polyglutamine repeat lengths was labeled with enhanced green
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fluorescent protein, Httex1-72Q-EGFP, and expressed with
pcDNA3.1(-) plasmid vector. To label nuclei in live cells, a
NLS-tagged monomeric red fluorescent protein (RFP-NLS)
described by Kvam et al. (2009) was cotransfected in with Httex1-
72Q-EGFP and intrabody. All expression plasmids were prepared
using EndoFree Plasmid Maxi (Qiagen) and confirmed by DNA
sequencing.
Cell culture and transfection
Undifferentiated ST14A cells were cultured at the permissive
temperature (338C), according to standard protocols (Ehrlich
et al., 2001). ST14A cells were transiently transfected with
jetPEI DNA transfection reagent (Polyplus Transfection Inc.)
as previously described (Kvam et al., 2009). For all transfec-
tions, intrabody plasmids were applied at equal (1 : 1) ratios to
Httex1 plasmids, and cells were analyzed at either 24 or 48 h
post-transfection.
Live-cell imaging
ST14A cells transfected with Httex1-72Q-eGFP reporters
were imaged directly in 6-well culture dishes using an
Olympus IX70 inverted microscope equipped with an
Olympus IXFLA Inverted Reflected Light Fluorescence
Observation attachment and RGB Mirror Cube filter wheel
(Olympus). Cells were observed without fixation using a 406
lens, and images were captured at either 24 or 48 h post-
transfection with a SPOT RT Color CCD camera using SPOT
Advanced software (Diagnostic Instruments). Digital images
were overlayed using Adobe Photoshop.
Nuclear vs cytoplasmic counting
To quantify the subcellular differences in the expression of
Httex1-72Q-eGFP when co-transfected with the intrabodies, the
extent to which the GFP signal was found in cytoplasm was
counted in ST14A cells cotransfected with Httex1-72Q-EGFP,
RFP-NLS and either C4 scFv or VL12.3. A two proportion z-test
was then used to determine if a significant difference in the pro-
portion of cells with cytoplasmic GFP existed between groups.
In vivo weight and survival studies: bilateral AAV-C4 injections
into R6/1 mice
AAV2/1 C4 scFv-HA was produced at the University of Iowa
Vector core (Dr. B. Davidson, director), as previously
described. The B6.HD6/1 mice, genotype verified by PCR of
tail biopsy, were bilaterally intrastriatally injected at 7–9
weeks of age, with 2 ml of AAV2/1 anti-HTT C4 scFv (10e12
Vg/ml)/side. Injected mice were housed at no more than three
per cage with littermates, observed daily and weighed weekly.
All animal procedures were approved by the Wadsworth
Center Institutional Animal Care and Use Committee. The
comparisons to intrastriatal injections of VL12.3 were made to
the published data by Southwell et al. (2009).
Immunostaining and confocal imaging after intrastriatal
injection
HDR6/1 mice were injected at 11 weeks of age. At 20 weeks of
age, injected mice were perfused with 4% paraformaldehyde,
brains stored in the same fixative for 20 h, then permeated in
15% sucrose prior to the preparation of 30-micron frozen
sections on a sliding microtome. Sections were selected for fluor-
escence double-labeling using antibodies to mutant Huntingtin
(mHtt) protein (EM48) and Alexa 488-labeled secondary
antibodies, and then antibodies to HA and Alexa 594-labeled
secondary antibodies, sequentially. Image capture and analysis
were performed on a Leica TCS SP5 confocal microscope.
Results and discussion
We have noted over several years of cellular and in vivo
experiments that the localization of Httex1-72Q-eGFP differs
between C4 scFv and VL12.3 transductions, with the former
clearly much more cytoplasmic. In order to specifically
examine the differences between the two intrabodies in situ, a
set of live imaging experiments was performed. ST14A cells
were transfected with Httex1-72Q-GFP and either C4 scFv,
VL12.3, or empty vector control. To label nuclei in live cells,
we additionally transfected a NLS-tagged monomeric RFP in
these cotransfection experiments. While not all cells were trans-
duced with all three plasmids, we have previously reported that
multiple plasmids appear to transduce cells in common when
delivered together (LeCerf et al., 2001;Miller et al., 2005).With
live cell imaging at 24 and 48 h, the Httex1-72Q-eGFP com-
bined with an empty vector control appears primarily aggregated
with very few cells displaying diffuse cytoplasmic Httex1-72Q-
GFP expression (Fig. 2A and B; color supplemental Fig. S2A
and B). Cells co-transfected with C4 scFv displayed a diffuse
Httex1-72Q-eGFP expression in the cytoplasm with lower levels
in nuclei in 62.5% of the cells (Table I). Rare aggregates are
only located in the cytoplasm (Supplementary Fig. S1B).
In contrast, with VL12.3 co-transfection, only 10.5% of the
Httex1-72Q-eGFP cotransfected cells displayed predominantly
cytoplasmic GFP (Table I). The diffuse material is noticeably
stronger in the nucleus of many of these cells (Fig. 2A and B,
Supplementary Fig. S1C). The clarity of the nucleus in these
observations is primarily determined by the plane of focus
and/or how recently the cells have divided; therefore, we have
grouped all of the non-cytoplasmic GFP cells together for the
purposes of this analysis. This difference in subcellular local-
ization is consistently observed over a range of experimental
protocols. An example from one of a large series of separate
experiments showing the same localization pattern is shown in












Supplementary Fig. S1C. While the VL12.3 co-transfection is
quite efficient at reducing the visible aggregation, any observ-
able aggregates appeared to be nuclear (Supplementary Fig.
S3C). As an additional control, we fused the MAPKK-NES
signal to both C4 scFv and VL12.3. These fusions successfully
removed Httex1-72Q-GFP from the nucleus in both cases, dem-
onstrating that the intrabody differences are not secondary to
changes in the nuclear membranes (Supplementary Figs S3B
and D).
Fig. 2. Httex1-72Q-eGFP is predominately cytoplasmic in cells cotransfected with either empty vector control or C4 scFv compared to VL12.3 at 24H (A) and
48H time points (B). ST14A cells were co-transfected with Httex1-72Q-eGFP and RFP-NLS (to label nuclei in live cells), and either empty vector control, C4
scFv or VL12.3. Live imaging was performed at 24 and 48 h. Bar ¼ 20 mm. A color version of this figure is available as supplementary data at PEDS Online.
Table I. The proportion of cells that have well-defined cytoplasmic GFP is








Total Proportion of cells
with cytoplasmic
GFP
C4 scFv 35 22 56 62.5%
VL12.3 6 51 57 10.5%











To confirm the cytoplasmic localization of C4 scFv in
brains, fixed tissue from AAV2/1 delivery of the C4 scFv intra-
body gene in vivo was examined using confocal microscopy.
B6.HD6/1 is an inbred HD transgenic mouse strain containing
Httex1 with CAG 120–125 plus 1 kb of upstream regulatory
DNA. For this experiment, the AAV was injected directly into
the striatum when the aggregates are starting to form at 11
weeks, and tissue was harvested at 20 weeks. The confocal
images (Fig. 3; color supplemental Fig. S4) clearly show four
cells in the field that have high expression of C4 scFv-HA, as
visualized with anti-HA and a red second antibody. In all four,
the center nuclear area is clear, while the red label wraps
around it in the cytoplasm. The transgene in this mouse does
not contain GFP, and is driven by an endogenous HTT pro-
moter, which leads to a relatively low level of observable
mHttex1 in the transgenic mouse brain compared with the
cellular co-transfection experiments. Diffuse Httex1 protein is
therefore not resolved in this experiment, although cells that
are not expressing the scFv-HA do show bright green aggre-
gated Httex1 protein when stained with the EM48 antibody.
Equivalent confocal images from AAV2/1 delivery of VL12.3
into transgenic mouse brains are not available; however, the
authors of the extensive in vivo study clearly state that the
complex is localized to the nucleus in vivo (Southwell et al.,
2009).
Intrastriatal injection would not be expected to counteract
the systemic phenotype of weight loss; however, disease onset
could be generally accelerated if the construct has a mild toxic
effect on the brain over weeks to months. Southwell et al.
(2009) reported that while VL12.3 could counteract short-term
effects of highly overexpressed Httex1, HDR6/2 transgenic
mice injected intrastriatally with AAV2/1-VL12.3 showed an
earlier onset of weight loss (Southwell, Fig. 9A), and acceler-
ation of premature death (Southwell, Fig. 9E), when compared
with mice that received a non-intrabody expressing AAV. We
therefore assessed our data on similarly injected mice that
received AAV2/1-C4 scFv produced at the same facility. We
used a slightly less aggressive exon1 fragment model HDR6/1,
where both the weight loss and the premature death start at a
later age. It is clear from our data that intrastriatal injection
of the AAV2/1-C4 scFv construct does not significantly worsen
the pathogenic weight loss that characterizes late-stage disease,
nor does it accelerate the start of the terminal period (Table II).
This is a critical safety issue before moving forward with more
global therapeutic intrabody expression.
The combined live cell imaging and injected HD transgenic
mouse tissue studies clearly show that the two intrabodies
elicit distinctly different subcellular distributions of target.
Given multiple human and animal model studies showing tran-
scriptional dysregulation and prominent neuronal intranuclear
inclusions in HD, the strongest hypothesis to explain the dif-
ferences in efficacy after intrabody gene delivery is that having
the antigen–antibody complex in the nucleus is sub-optimal.
It is unclear whether the downstream effect is on the formation
of aggregates, or their clearance (see Southwell et al., 2009;
Butler et al., 2012) but the overall need to consider sub-
cellular localization can inform development of intrabody
reagents for HD and several other degenerative diseases trig-
gered by a breakdown in proteostasis.
At the mechanistic/structural level, the structures of the
HTT N-terminal peptides complexed with VL12.3 and
C4 scFv are now available (Schiefner et al., 2011; De Genst,
unpublished data). Appreciation of the extent to which the
structure and post-translational modification of the highly con-
served AA 1-17 domain affects the localization and possibly
other protein interactions of HTT is emerging rapidly. While
there are differences in the contact residues in the two intra-
body–peptide complexes, these do not immediately reveal
why there are such sharp differences in the cellular behavior
of the two intrabodies. Although the selections were to a very
similar region of the N-terminal HTT, the differences in sec-
ondary structures of the peptides that do or do not include the
first three AAs of the polyQ domain might be sufficient to
alter the output in a critical manner.
At the cellular screening level, as more mechanistic infor-
mation (La Spada and Taylor, 2010; Zuccato et al., 2010;
Crook and Housman, 2011) and better cell lines (An et al.,
2012; Jeon et al., 2012; Ward and La Spada, 2012; Kaye and
Finkbeiner, 2013) are becoming available, it should be pos-
sible to design screening paradigms that utilize this informa-
tion at earlier stages of the intrabody drug development
process. Consideration of the need for fusion constructs can
Fig. 3. Confocal images of striatal sections confirm cytoplasmic
co-localization of mHttex1 with C4 scFv-HA in vivo. Mouse was injected at
11 weeks, sacrificed at 20 weeks. Anti-htt EM48 (green) anti-HA (red) Bar ¼
20 mm. A color version of this figure is available as supplementary data at
PEDS Online.
Table II. Intrastriatal injection of the AAV2/1-C4 scFv construct does not
accelerate the pathogenic weight loss in HDR6/1 transgenic mice



































also be incorporated when comparing candidates (Butler et al.,
2012).
Once we are confident that we know where as well as what
we need to target, antibody engineering can provide fusion
protein approaches to manipulate the localization, as we have
shown above. The NES experiment is largely a proof of
concept, since there are issues of altered solubility, immuno-
genicity and kinetics of the compartmentalization in different
cell types, including those where the mutant gene may be
interacting with membranes. It may also be necessary to create
multifunctional constructs that can target the mutant protein
for degradation in addition to other localization signals (Butler
and Messer, 2011; Joshi et al., 2012; Messer and Joshi, 2013).
However, these challenges are already being addressed in the
use of antibody engineering for cancer and toxin clearance,
suggesting that additional tools to tackle neurodegenerative
diseases will be available for future studies as they have been
to date.
Supplementary data
Supplementary data and color figures are available at PEDS
online.
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